Stocks
AstraZeneca and Amgen's Cancer Treatment Combination Shows Promising Results
AstraZeneca and Amgen have announced that their Phase 3 DeLLphi-305 study has met its primary endpoint. The trial is investigating the use of Lynparza (olaparib) in combination with durvalumab in patients with previously untreated advanced urothelial carcinoma. This achievement could be a significant step forward for cancer treatment.
The results show that the combination of Lynparza and durvalumab has improved overall survival rates compared to durvalumab alone, according to the companies. However, it is essential to note that backtested performance of this strategy may not reflect actual trading or market conditions.